做新能源汽车、做高端智能手机、做酒旅品牌、做航空服务…… 追觅近期不断曝出跨界开拓新业务，甚至其CEO俞浩还曾表示要打造人类历史上第一个百万亿美金公司。 看到如此疯狂的追觅，许多人都想起了曾经生态化反模式的乐视，以及为梦想窒息但至今在美国没有回国 的贾跃亭。 有意思的是，追觅CEO俞浩今日发文，回应了追觅是不是下一个乐视的问题。他认为追觅和乐视完全不一 样，而这个不一样主要有3点体现。 首先是乐视没有解决全球化问题，而追觅解决了全球化问题。他透露追觅海外市场营收占比高达80%，利 润占比还更高。 其次乐视没有解决高端化问题，而追觅解决了高端化问题，并且在各个赛道都是高端的，主业还做到了行 业利润第一。 最后就是乐视没有解决研发创新的问题，而追觅每年大量研发投入且有效创新，做出了消费者买单的创新 功能。 简单来说，俞浩认为追觅解决了市场、品牌以及技术创新的问题，而这在全球企业中都罕见，支撑着追觅 每年业绩百分百增长，业务不断跨界和升级。 虽然俞浩这样回答，但许多细节都经不起推敲。比如他说追觅解决了高端化问题，追觅主业利润行业第一 高，但很明显这两者之间没有必然的联系。而且就算追觅品牌足够高端，但跨界到其他行业， ...

Core Insights - The company "Raising a Cow" aims to achieve over 7 billion yuan in revenue by 2025, representing a growth of approximately 40% from over 5 billion yuan in the previous year, highlighting its strong market performance despite industry challenges [1] - The company has established a comprehensive supply chain with 10 dairy farms and 4 beef farms, maintaining a self-sufficiency rate of over 95% for milk sources, which contributes to its operational efficiency [2] - The Chinese dairy market, valued at over 650 billion yuan, presents significant growth potential, and "Raising a Cow" has developed a diverse product matrix to meet segmented consumer demands [3] Group 1 - The company has achieved a notable market position, ranking among the top ten in the national dairy industry, despite being a relatively young brand established less than ten years ago [1] - The company has a robust offline presence, covering nearly 30 provincial-level administrative regions and entering major retail chains such as Yonghui Supermarket and RT-Mart [1] - The company’s innovative approach includes launching products like A2 β-casein organic milk to cater to specific consumer preferences, supported by ongoing research collaborations with institutions like China Agricultural University [2] Group 2 - The company has built a solid foundation through a twelve-year commitment to a full supply chain, starting with establishing farms before branding [1][2] - The company’s A2 β-casein milk series has ranked first in national sales for three consecutive years, demonstrating its competitive advantage in niche markets [3] - Future strategies include deepening supply chain integration, enhancing digital capabilities, and continuing product innovation to meet diverse consumer needs [3]

IT之家 1 月 27 日消息，追觅科技创始人兼 CEO 俞浩昨晚在社交媒体发布长文，表示经常有人问追觅是不是下一个乐视？俞浩称"完全不一样"。 1、乐视没有解决全球化的问题，只是在中国卷。追觅解决了全球化的问题，追觅海外市场占收入的 80%，利润占比更高。 3、乐视没有解决研发创新的事情。追觅每年大量的研发投入，且进行了有效的创新，支撑了全球的高端。如何把上万名研发工程师组织起来， 做出有效的，消费者买单的创新功能，这是非常难的。追觅解决了这个问题。 这三个突破，在中国企业，乃至全球企业中都是非常罕见的。这才是支撑追觅每年业绩百分百增长，业务不断跨界和升级的核心能力！ 2、乐视没有解决高端化的问题。追觅解决了高端化的问题，追觅在各个赛道都是高端的，主业做到了行业利润第一。高端品牌和性价比品牌， 利润要高非常多。第一名吃肉，第二名喝汤，第三名就很难了。而追觅在全球范围内都是高端的。高端品牌的利润，是性价比品牌的好多倍。 IT之家注意到，俞浩在评论区中回应了裁员传闻，表示历史上整体裁员非常少，只有过一次，去年六七月，中国区人效太低，要提高人效。俞浩还称"核心 人员很稳定"。 那你们电商板块为啥裁员啊 昨天 19 ...

（编辑 楚丽君） 证券日报网讯 1月26日，万盛股份在互动平台回答投资者提问时表示，公司股价表现受多重外部因素叠 加影响：全球层面，国际地缘冲突、欧美通胀压力仍在持续，全球经济复苏乏力导致化工产品终端需求 不及预期；国内层面，行业产能结构性扩张带来供给侧竞争加剧，主要产品出现阶段性供大于求，直接 导致产品毛利及毛利率承压下滑。面对行业普遍的经营压力，公司管理层始终积极应对：一方面持续强 化研发创新与市场开拓，稳步推进高附加值产品布局；另一方面深入开展降本增效，已实现营业收入同 比增长，经营性现金流保持稳定流入，但受大额固定资产折旧摊销、资产减值等因素影响，公司经营业 绩仍面临较大压力。关于回购，公司的回购计划自公司股东会审议通过回购股份方案之日起12个月内 （即2025年4月29日～2026年4月28日）通过二级市场回购，回购的股份用于注销。公司严格按照既定方 案，结合二级市场股价波动、交易窗口期等实际情况有序实施，不存在任何"打压股价后买入"的行为， 公司将根据二级市场情况及既定的方案有序推进回购股份的事宜，并在每个月的月初披露股份回购的进 展公告。 ...

Core Viewpoint - Junlebao Dairy Group has submitted its main board listing application to the Hong Kong Stock Exchange, marking a new phase in its development as a leading comprehensive dairy enterprise in China [1] Financial Performance - Junlebao's total revenue is projected to grow from RMB 17.5 billion in 2023 to RMB 19.8 billion in 2024, with RMB 15.1 billion achieved in the first nine months of 2025, indicating steady revenue growth [3] - Adjusted net profit is expected to rise from RMB 600 million in 2023 to RMB 1.16 billion in 2024, reaching RMB 940 million in the first nine months of 2025, with adjusted net profit margin increasing from 3.4% in 2023 to 5.9% in 2024 and further to 6.2% in 2025 [3] Market Presence - Junlebao's sales network covers all 31 provincial-level administrative regions in China, penetrating approximately 2,200 districts and counties, which is about 77% of the total county-level administrative regions [4] - The company has established partnerships with over 5,500 distributors and has products available at around 400,000 retail terminals for low-temperature liquid milk and 70,000 for formula milk [4] Product Focus - The low-temperature liquid milk segment, including fresh milk and low-temperature yogurt, is the fastest-growing area in China's dairy market, with Junlebao leading this growth [5] - Junlebao's "Yuexianhuo" brand has achieved a 24.0% market share in the high-end fresh milk market, while the "Jianchun" brand has become the leading low-temperature yogurt brand in China [5][6] Competitive Advantage - Junlebao's core competitiveness lies in its integrated operation model covering dairy farming, R&D, production, and distribution, with a self-sufficiency rate of 66% for milk sources as of 2024 [7] - The company has established a leading R&D platform, collaborating with top research institutions and universities, which supports product innovation and quality assurance [7] Industry Outlook - The Chinese dairy market is projected to reach RMB 653.5 billion in 2024, with per capita consumption significantly below the global average, indicating substantial growth potential [8] - Junlebao's upcoming listing aims to raise funds for factory construction, capacity upgrades, brand promotion, and enhancing R&D capabilities, which will support sustainable growth [8]

Core Viewpoint - Junlebao Dairy Group has submitted its main board listing application to the Hong Kong Stock Exchange, marking a significant milestone in its development as a leading comprehensive dairy enterprise in China [1] Financial Performance - Junlebao's total revenue is projected to grow from RMB 17.5 billion in 2023 to RMB 19.8 billion in 2024, with RMB 15.1 billion achieved in the first nine months of 2025, indicating steady revenue growth [3] - Adjusted net profit is expected to rise from RMB 600 million in 2023 to RMB 1.16 billion in 2024, reaching RMB 940 million in the first nine months of 2025, with adjusted net profit margin increasing from 3.4% in 2023 to 5.9% in 2024 and further to 6.2% in 2025 [3] Market Presence - Junlebao's sales network covers all 31 provincial-level administrative regions in China, penetrating approximately 2,200 districts and counties, which accounts for about 77% of the total county-level administrative regions [4] - The company has established partnerships with over 5,500 distributors and has successfully entered the Hong Kong and Macau markets, with plans to expand into Southeast Asia [4] Product Focus - The low-temperature liquid milk segment, including fresh milk and low-temperature yogurt, is the fastest-growing area in China's dairy market, with Junlebao leading this growth [5][6] - Junlebao's "Yuexianhuo" brand has captured a 24.0% market share in the high-end fresh milk market, while the "Jianchun" brand has become the leading brand in the low-temperature yogurt category [5][6] Operational Strength - Junlebao operates 33 modern self-owned farms and 20 dairy production facilities, with a dairy cow inventory of 192,000, ranking third in the country [7] - The company has a self-sufficiency rate of 66% for milk sources, the highest among large comprehensive dairy enterprises in China [7] Industry Opportunities - The Chinese dairy market is projected to reach RMB 653.5 billion in 2024, with per capita consumption significantly below the global average, indicating substantial growth potential [8] - The penetration rate of low-temperature liquid milk is expected to increase from 25.3% in 2024 to 31.8% by 2029, representing a key growth avenue [8] - Funds raised from the listing will be used for factory upgrades, capacity expansion, brand marketing, and research innovation, supporting Junlebao's long-term strategy [8]

Core Viewpoint - The steel tape measure industry in Yu County, Henan, has evolved from a small-scale, family workshop model to a comprehensive industrial ecosystem, producing 1.5 billion units annually, accounting for 85% of China's market and over 65% of the global market, with an annual output value of 12 billion yuan [3][4]. Group 1: Industry Development - Yu County has over 2,000 steel tape measure companies, showcasing a complete industrial chain from R&D to production and sales [3]. - The industry has seen significant innovation, with companies introducing high-end products such as laser measuring tape and hollow steel tape measures, enhancing functionality and aesthetic appeal [4][7]. - The introduction of smart automation production lines has increased production efficiency by over 50% [6]. Group 2: Product Innovation - Companies are focusing on R&D to create differentiated and higher-quality products, responding to market demands and leading innovation [5][6]. - The hollow steel tape measure, which has 39 patents and a lifespan three times longer than standard models, has seen sales grow from 6 million units in 2022 to over 30 million units projected for 2025 [6][8]. - New product features include laser measurement modules and multifunctional designs, catering to diverse user needs [7]. Group 3: Market Expansion - Companies are actively expanding their market presence through cross-border e-commerce platforms, achieving stable shipments in the European and American markets [8][10]. - The establishment of a bonded logistics center in Yu County has facilitated steel tape measure exports, enhancing the region's foreign trade capabilities [9]. - Companies are also building overseas warehouses to improve product exposure and expedite shipping [9][10]. Group 4: Brand Development - The industry is shifting towards brand creation, with companies like Yu County's Xuan Shi focusing on building brand recognition and increasing product value [11][12]. - The dual-brand strategy allows companies to operate under different trademarks in domestic and international markets, enhancing brand presence [12][13]. - Efforts to participate in global exhibitions and obtain international certifications are underway to boost brand visibility and support high-end market transitions [13].

Core Viewpoint - Junlebao Dairy Group has submitted its application for a mainboard listing on the Hong Kong Stock Exchange, highlighting its strong market position and comprehensive competitive edge in the dairy industry after 30 years of operation [1]. Financial Performance - Junlebao's total revenue is projected to grow from RMB 17.5 billion in 2023 to RMB 19.8 billion in 2024, with RMB 15.1 billion achieved in the first nine months of 2025, indicating steady revenue growth [3]. - Adjusted net profit is expected to rise from RMB 600 million in 2023 to RMB 1.16 billion in 2024, reaching RMB 940 million in the first nine months of 2025, with adjusted net profit margin increasing from 3.4% in 2023 to 5.9% in 2024 and further to 6.2% in 2025 [3]. Market Presence - Junlebao's sales network covers all 31 provincial-level administrative regions in China, penetrating approximately 2,200 districts and counties, which accounts for about 77% of the total county-level administrative regions [4]. - The company has established partnerships with over 5,500 distributors and has successfully entered the Hong Kong and Macau markets, with plans to expand into Southeast Asia [4]. Product Focus - The low-temperature liquid milk segment, including fresh milk and low-temperature yogurt, is the fastest-growing area in China's dairy market, with Junlebao leading this growth [6]. - Junlebao's "Yuexianhuo" brand has achieved a 24.0% market share in the high-end fresh milk market, while the "Jianchun" brand has become the leading brand in the low-temperature yogurt category [6]. Operational Strength - Junlebao operates 33 modern self-owned farms and 20 dairy production facilities, with a dairy cow inventory of 192,000, ranking third in the country [7]. - The company has a self-sufficiency rate of 66% for milk sources, the highest among large comprehensive dairy enterprises in China, ensuring product quality and safety [7]. Industry Outlook - The Chinese dairy market is projected to reach RMB 653.5 billion in 2024, with per capita consumption significantly below the global average, indicating substantial growth potential [8]. - Junlebao's upcoming IPO aims to raise funds for factory upgrades, channel expansion, R&D innovation, and digital transformation, which will strengthen its competitive advantage in the industry [8].

Core Viewpoint - The company, 半亩花田, is attempting to become the first domestic beauty brand listed on the Hong Kong Stock Exchange, showcasing impressive revenue growth but facing significant challenges related to high marketing costs, declining R&D investment, and product quality complaints [1][4][18]. Financial Performance - For the first three quarters of 2023, 半亩花田 reported a revenue of 18.95 billion RMB, with a net profit increase of 197.2% [1]. - The company's revenue for 2023, 2024, and the first nine months of 2025 is approximately 11.98 billion RMB, 14.99 billion RMB, and 18.95 billion RMB, respectively [4][5]. - The gross profit margin has consistently remained above 60%, but the adjusted net profit margin has not exceeded 10%, standing at about 7.8% [4][5]. Marketing and Sales Strategy - 半亩花田's marketing strategy relies heavily on celebrity endorsements, KOL collaborations, and social media promotions, with marketing expenses accounting for nearly 50% of total revenue [1][2]. - Monthly marketing expenses approached 1 billion RMB in the first three quarters of 2025, while the cost of acquiring customers on platforms like Douyin has increased by over 30% [3]. R&D Investment - R&D expenditure has been declining, with its proportion of total revenue dropping from 2.4% to 1.5% between 2023 and 2025 [3][4]. - In contrast, leading domestic brands like 珀莱雅 and 薇诺娜 invest 3%-5% of their revenue in R&D, creating a competitive edge [7]. Cash Flow and Financial Health - As of September 2025, the company's asset-liability ratio was 67.6%, indicating high financial leverage [8]. - The operating cash flow for the first nine months of 2025 was approximately 1.37 billion RMB, but financing cash flow turned negative starting in 2024 [8][9]. - The company has a total of about 1.47 billion RMB in bank loans and liabilities, while cash reserves are only 1.62 billion RMB, indicating tight liquidity [8]. Quality Control and Consumer Complaints - The company has faced quality control issues, including a significant number of consumer complaints related to product safety and effectiveness, with 280 complaints recorded on the Black Cat complaint platform [12][16]. - Regulatory inspections have revealed non-compliance with safety standards, which could harm the brand's reputation [12][18].

Core Viewpoint - Yiling Pharmaceutical (002603.SZ) is expected to turn a profit in 2025, with net profit and net profit excluding non-recurring items projected to reach between 1.2 billion to 1.3 billion yuan, and basic earnings per share expected to rise to between 0.72 yuan and 0.78 yuan [1][2]. Financial Performance - The net profit attributable to shareholders is forecasted to be between 1.2 billion and 1.3 billion yuan, a significant recovery from a loss of approximately 724.5 million yuan in the same period last year [2]. - The net profit excluding non-recurring items is also expected to be between 1.2 billion and 1.3 billion yuan, compared to a loss of about 792.5 million yuan in the previous year [2]. - Basic earnings per share are projected to improve to between 0.72 yuan and 0.78 yuan, up from a loss of 0.43 yuan per share in the prior year [2]. Strategic Initiatives - 2025 is identified as a critical year for the company's "13th Five-Year Plan," focusing on long-term development amidst market complexities and competitive pressures [3]. - The company is enhancing budget management and establishing a comprehensive cost control system, leading to improved profit margins [3]. - Significant investment in R&D, with 544 million yuan allocated in the first three quarters of 2025, representing 9.27% of revenue, positions the company as a leader in the traditional Chinese medicine sector [3]. Product Development - Core products such as Qiliqiangxin Capsules and Tongxinluo Capsules have received validation from international medical journals, supporting their market promotion [3]. - The company is seeing notable sales growth in patented traditional Chinese medicine products, with Baizi Bujin Capsules becoming a major OTC product exceeding 100 million yuan in sales [3]. Expansion into Chemical Drugs - The company is actively expanding into the chemical drug sector, with several innovative drugs entering clinical trials [5]. - The approval of the chemical drug Anilofen Injection, the first patented chemical drug from its subsidiary Yiling Wanzhou, marks a significant milestone for the company [5]. - Anilofen Injection is positioned as a new treatment option for postoperative pain management, enhancing the company's product pipeline in the chemical drug market [5]. Industry Context - The continuous decline in traditional Chinese medicine material prices since mid-2024 has positively impacted the company's performance, alleviating cost pressures [6]. - The comprehensive price index for traditional Chinese medicine materials has decreased from nearly 3600 points in July 2024 to 2556 points by January 2026, returning to early 2021 levels [6]. - Analysts from various firms have recognized the company's strong R&D and sales capabilities, suggesting a valuation premium due to its strategic positioning in both traditional and chemical medicine sectors [6].